Contact Center Industry News

TMCNet:  Altravax, Inc. Awarded $3.45 Million in NIH Funds for Vaccines to HIV/AIDS

[December 03, 2012]

Altravax, Inc. Awarded $3.45 Million in NIH Funds for Vaccines to HIV/AIDS

FARGO, N.D. & SUNNYVALE, Calif. --(Business Wire)--

Altravax, Inc. announced today that it has been awarded two research grants worth a total of $3.45 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1. UNAIDS, the Joint United Nations Programme on HIV/AIDS, reported that between 2.2 to 2.8 million people, including 330,000 children, were newly infected with HIV in 2011, bringing the total number of people living with AIDS to over 34 million. Altravax will use its proprietary MolecularBreeding™ directed evolution technology to create vaccines that provide broad protection against the various strains of HIV-1. The existence of a large number of virus strains and the continued changing nature of the virus is one of the major challenges facing the development of vaccines for HIV/AIDS.

Dr. Robert Whalen, the Chief Scientific Officer atAltravax, is a leader in the application of the MolecularBreeding™ technology platform to vaccine development. "We are pleased that the NIH has recognized the value of our technology in the search for an HIV vaccine. Our proposal to create vaccines that can more effectively stimulate the immune system represents a novel approach, and the recent award of these two grants will allow us to thoroughly explore this possibility. The current lack of viable vaccine candidates limits the ability of biotechnology companies to invest in HIV vaccine research with their own funds. We appreciate the federal government's willingness to support the goal of a preventative vaccine to combat the AIDS epidemic," said Dr. Whalen.

Altravax's latest research on vaccines for HIV/AIDS, performed by Dr. Kristin Narayan and colleagues from Altravax in collaboration with The Scripps Research Institute, will soon be published in the scientific journal PLoS ONE, an international, peer-reviewed, open-access, online publication.

In January 2010, Altravax acquired from Maxygen, Inc. (Nasdaq: MAXY) exclusive rights to the MolecularBreeding™ technology platform for the development of vaccines to infectious diseases. The Company has a focused product pipeline including vaccines to prevent or treat several infectious diseases.

About Altravax, Inc.

Altravax, Inc. is a privately held biopharmaceutical company with headquarters in Fargo, ND and research laboratories in Sunnyvale, CA (News - Alert). Altravax was founded based on the strength of a proven technology platform that can produce novel vaccine candidates with the potential to protect humans from infectious diseases and improve health globally.

[ Back To Cloud Contact Center's Homepage ]


Featured Resources

Featured Report
Millennial Research on Customer Service Expectations

Millennial Research on Customer Service Expectations

The "why" behind this research is simple: our clients recognize that different generations bring different expectations, varied communication preferences and new customer service patterns to the customer experience...
Featured Report
Optimizing the Customer Experience through Cloud Contact Centers

Optimizing the Customer Experience through Cloud Contact Centers

Adoption of cloud contact centers is on the rise. Findings from Aberdeen's January 2014 'Public Cloud vs. On-Premise: How to More Effectively Deploy a Cloud Center' study shows that 31% of contact centers are deployed in the cloud, and our related blog post highlights that companies anticipate their adoption of cloud technology to rise further throughout 2014...
Featured Report
Aberdeen report

Aberdeen Report: Cloud for Mid-Sized Contact Centers – What You Must Know

Cloud Technology is opening new doors for many businesses. However, it does so only when it's combined with the use of best practices and key technology enablers. This document highlights the adoption of cloud technology by mid-size contact centers and illustrates the reasons driving their investments...
Featured Whitepaper
Aberdeen report

Seven Critical Capabilities to Demand From Your Cloud Contact Center Provider

To deliver a world-class customer experience, your contact center must be flexible and reliable, while providing all the tools agents and supervisors need to manage their workflows. Here are seven critical capabilities to look for when deploying a contact center in the cloud...
Featured Webinar

Contact Center Economics and the Cloud

Together, Bob and Drew will help you understand the economic value of upgrading technology, important business and financial considerations, and how to compare total cost of ownership of a premises vs. cloud or hosted solution. Watch the webinar on-demand now...
Featured Datasheet
Zipwire Cloud Contact Center

Zipwire Cloud Contact Center

The appeal of moving services to the cloud is obvious. Cloud services offer reliability and robust feature sets without the need to implement or maintain complex contact center infrastructure. The Zipwire™ cloud-based contact center allows businesses to leverage the flexibility and cost savings of cloud architecture while offering a seamless, first-class customer experience...